Send us Feedback

Abraxis BioScience (ABII)
Analysis
SUMMARY
BULLS
BEARS
TOPICS
Data
DATA CENTRAL
STOCK CHART
Financials
SEC FILINGS
BALANCE
INCOME
CASH FLOW

ABII » Topics » SIGNATURES

This excerpt taken from the ABII 10-K filed Mar 12, 2010.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Los Angeles, State of California on the 12th day of March, 2010.

 

ABRAXIS BIOSCIENCE, INC.
By:  

/s/    BRUCE J. WENDEL

    Bruce J. Wendel
  Chief Executive Officer
This excerpt taken from the ABII 8-K filed Feb 5, 2010.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

      ABRAXIS BIOSCIENCE, INC.
Date: February 5, 2010     By:  

/s/    BRUCE WENDEL        

        Bruce Wendel
        Chief Executive Officer
This excerpt taken from the ABII 8-K filed Jan 28, 2010.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

        ABRAXIS BIOSCIENCE, INC.
Date: January 28, 2010     By:  

/s/    PATRICK SOON-SHIONG        

      Patrick Soon-Shiong
      Executive Chairman
This excerpt taken from the ABII 8-K filed Dec 15, 2009.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    ABRAXIS BIOSCIENCE, INC.
  Date: December 14, 2009     By:   /s/    RICK RODGERS        
       

Rick Rodgers

Senior Vice President and Chief Financial Officer

This excerpt taken from the ABII 8-K filed Nov 5, 2009.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    ABRAXIS BIOSCIENCE, INC.
Date: November 5, 2009   By:   /s/Richard Rodgers
   

Richard Rodgers

Senior Vice President and Chief Financial Officer

 

This excerpt taken from the ABII 8-K filed Aug 12, 2009.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    ABRAXIS BIOSCIENCE, INC.
Date: August 12, 2009     By:   /s/ Richard Rodgers
     

Richard Rodgers

Chief Financial Officer

 

This excerpt taken from the ABII 8-K filed Aug 6, 2009.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    ABRAXIS BIOSCIENCE, INC.
Date: August 6, 2009     By:   /s/   Richard Rodgers
       

Richard Rodgers

Senior Vice President and Chief Financial Officer

 

This excerpt taken from the ABII 8-K filed Jul 15, 2009.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    ABRAXIS BIOSCIENCE, INC.
Date: July 15, 2009     By:   /s/ Leon O. Moulder, Jr.
     

Leon O. Moulder, Jr.

President and Chief Executive Officer

This excerpt taken from the ABII 10-Q filed May 19, 2009.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

ABRAXIS BIOSCIENCE, INC.
By:   /s/ DAVID D. O’TOOLE
  David D. O’Toole
  Executive Vice President and Chief Financial Officer
  (Principal Financial and Accounting Officer)

Date: May 19, 2009

This excerpt taken from the ABII 10-Q filed May 8, 2009.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

ABRAXIS BIOSCIENCE, INC.
By:   /s/ DAVID D. O’TOOLE
  David D. O’Toole
  Executive Vice President and Chief Financial Officer
  (Principal Financial and Accounting Officer)

Date: May 8, 2009

 

31

Table of Contents
This excerpt taken from the ABII 8-K filed May 7, 2009.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  ABRAXIS BIOSCIENCE, INC.
Date: May 7, 2009   By:  

/s/    David D. O’Toole

    David D. O’Toole
    Chief Financial Officer

This excerpt taken from the ABII 8-K filed May 1, 2009.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    ABRAXIS BIOSCIENCE, INC.
Date: May 1, 2009     By:   /s/ David D. O’Toole
      David D. O’Toole
      Chief Financial Officer
These excerpts taken from the ABII 10-K filed Apr 30, 2009.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Los Angeles, State of California on the 30th day of April 2009.

 

ABRAXIS BIOSCIENCE, INC.

By:

  

/S/    LEON O. MOULDER, JR.

Leon O. Moulder, Jr.

President and Chief Executive Officer

 

29

SIGNATURES

STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:3px;line-height:95%; vertical-align:top">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Los Angeles, State of California on the 30thFACE="Times New Roman" SIZE="2"> day of April 2009.

 

















ABRAXIS BIOSCIENCE, INC.

By:

 

/S/    LEON O. MOULDER,
JR.

Leon O. Moulder, Jr.

SIZE="2">President and Chief Executive Officer

 


29







EX-31.1
2
dex311.htm
CERTIFICATION OF CEO PURSUANT TO SECTION 302


Certification of CEO pursuant to Section 302



This excerpt taken from the ABII 8-K filed Apr 13, 2009.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    ABRAXIS BIOSCIENCE, INC.
  Date: April 13, 2009     By:   /s/ David D. O’Toole
        David D. O’Toole
        Chief Financial Officer
These excerpts taken from the ABII 10-K filed Mar 6, 2009.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Los Angeles, State of California on the 6th day of March, 2009.

 

ABRAXIS BIOSCIENCE, INC.
By:  

/s/    PATRICK SOON-SHIONG, M.D.

    Patrick Soon-Shiong, M.D.
 

Chairman of the Board of Directors and

Chief Executive Officer

SIGNATURES

STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:3px;line-height:95%; vertical-align:top">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Los Angeles, State of California on the 6thFACE="Times New Roman" SIZE="2"> day of March, 2009.

 

























ABRAXIS BIOSCIENCE, INC.
By: 

/s/    PATRICK SOON-SHIONG, M.D.

  Patrick Soon-Shiong, M.D.
 

Chairman of the Board of Directors and

ALIGN="center">Chief Executive Officer

This excerpt taken from the ABII 8-K filed Mar 3, 2009.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  ABRAXIS BIOSCIENCE, INC.

Date: March 3, 2009

   By:   /s/ David D. O’Toole
    David D. O’Toole
    Chief Financial Officer

This excerpt taken from the ABII 8-K filed Jan 8, 2009.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  ABRAXIS BIOSCIENCE, INC.
Date: January 8, 2009   By:  

/s/ David D. O’Toole

    David D. O’Toole
    Chief Financial Officer
This excerpt taken from the ABII 8-K filed Nov 24, 2008.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    ABRAXIS BIOSCIENCE, INC.
Date: November 24, 2008     By:   /s/ David D. O’Toole
        David D. O’Toole
        Chief Financial Officer
This excerpt taken from the ABII 10-Q filed Nov 14, 2008.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

ABRAXIS BIOSCIENCE, INC.
By:  

/s/ DAVID D. O’TOOLE

  David D. O’Toole
 

Executive Vice President and Chief Financial Officer

(Principal Financial and Accounting Officer)

Date: November 14, 2008

 

33

Table of Contents
This excerpt taken from the ABII 8-K filed Nov 14, 2008.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    ABRAXIS BIOSCIENCE, INC.
Date: November 14, 2008     By:   /s/ David D. O’Toole
        David D. O’Toole
        Chief Financial Officer

This excerpt taken from the ABII 8-K filed Sep 12, 2008.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    ABRAXIS BIOSCIENCE, INC.
Date: September 12, 2008     By:   /s/ David O’Toole
        David O’Toole
        Chief Financial Officer
This excerpt taken from the ABII 8-K filed Sep 5, 2008.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    ABRAXIS BIOSCIENCE, INC.
Date: September 5, 2008     By:   /s/ David O’Toole
     

David O’Toole

Chief Financial Officer

This excerpt taken from the ABII 10-Q filed Aug 14, 2008.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

ABRAXIS BIOSCIENCE, INC.
By:  

/s/ DAVID D. O’TOOLE

 

David D. O’Toole

Executive Vice President and Chief Financial Officer

(Principal Financial and Accounting Officer)

Date: August 14, 2008

 

37

Table of Contents
This excerpt taken from the ABII 8-K filed Aug 13, 2008.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    ABRAXIS BIOSCIENCE, INC.
Date: August 13, 2008     By:   /s/ David D. O’Toole
       

David D. O’Toole

Chief Financial Officer

 

This excerpt taken from the ABII 8-K filed May 28, 2008.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    ABRAXIS BIOSCIENCE, INC.
Date: May 28, 2008     By:    /s/ Patrick Soon-Shiong
       

Patrick Soon-Shiong, M.D.

Chief Executive Officer

This excerpt taken from the ABII 8-K filed May 15, 2008.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  ABRAXIS BIOSCIENCE, INC.

Date: May 15, 2008

   By:  

/s/ Lisa Gopalakrishnan

    Lisa Gopalakrishnan
    Chief Financial Officer

This excerpt taken from the ABII 10-Q filed May 15, 2008.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

ABRAXIS BIOSCIENCE, INC.
By:   /s/ LISA GOPALAKRISHNAN
 

Lisa Gopalakrishnan

Executive Vice President and

Chief Financial Officer

(Principal Financial and Accounting Officer)

Date: May 15, 2008

 

40

Table of Contents
These excerpts taken from the ABII 10-K filed May 5, 2008.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Los Angeles, State of California on the 5th day of May 2008.

 

ABRAXIS BIOSCIENCE, INC.
By:  

/S/    PATRICK SOON-SHIONG, M.D.        

 

Patrick Soon-Shiong, M.D.

Chairman of the Board of Directors and

Chief Executive Officer

 

36

SIGNATURES

FACE="Times New Roman" SIZE="2">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, in
the City of Los Angeles, State of California on the 5th day of May 2008.

 





















ABRAXIS BIOSCIENCE, INC.
By: 

/S/    PATRICK
SOON-SHIONG, M.D.        

 

Patrick Soon-Shiong, M.D.

FACE="Times New Roman" SIZE="2">Chairman of the Board of Directors and

Chief Executive Officer

 


36







EX-31.1
2
dex311.htm
CERTIFICATION OF CEO PURSUANT TO SECTION 302


Certification of CEO pursuant to Section 302



This excerpt taken from the ABII 8-K filed Apr 1, 2008.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    ABRAXIS BIOSCIENCE, INC.

Date: April 1, 2008

     By:   /s/ Lisa Gopalakrishnan
       

Lisa Gopalakrishnan

Chief Financial Officer

This excerpt taken from the ABII 8-K filed Feb 12, 2008.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    ABRAXIS BIOSCIENCE, INC.
Date: February 12, 2008     By:   /s/ Lisa Gopalakrishnan
        Lisa Gopalakrishnan
        Chief Financial Officer
This excerpt taken from the ABII 10-Q filed Dec 20, 2007.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

ABRAXIS BIOSCIENCE, INC.
By:   /s/ LISA GOPALAKRISHNAN
  Lisa Gopalakrishnan
  Executive Vice President and Chief
  Financial Officer
  (Principal Financial and Accounting Officer)

Date: December 20, 2007

 

42

Table of Contents

EXCERPTS ON THIS PAGE:

10-K
Mar 12, 2010
8-K
Feb 5, 2010
8-K
Jan 28, 2010
8-K
Dec 15, 2009
8-K
Nov 5, 2009
8-K
Aug 12, 2009
8-K
Aug 6, 2009
8-K
Jul 15, 2009
10-Q
May 19, 2009
10-Q
May 8, 2009
8-K
May 7, 2009
8-K
May 1, 2009
10-K (2 sections)
Apr 30, 2009
8-K
Apr 13, 2009
10-K (2 sections)
Mar 6, 2009
8-K
Mar 3, 2009
8-K
Jan 8, 2009
8-K
Nov 24, 2008
10-Q
Nov 14, 2008
8-K
Nov 14, 2008
8-K
Sep 12, 2008
8-K
Sep 5, 2008
10-Q
Aug 14, 2008
8-K
Aug 13, 2008
8-K
May 28, 2008
8-K
May 15, 2008
10-Q
May 15, 2008
10-K (2 sections)
May 5, 2008
8-K
Apr 1, 2008
8-K
Feb 12, 2008
10-Q
Dec 20, 2007

RELATED TOPICS for ABII:

"SIGNATURES" elsewhere:

Genzyme (GENZ)
Accentia Biopharmaceuticals (ABPI)
Adherex Technologies (ADH)
Advanced Life Sciences Holdings (ADLS)
Anesiva (ANSV)
Artes Medical (ARTE)
ATS Medical (ATSI)
Celldex Therapeutics, Inc. (AVAN)
Avigen (AVGN)
Advancis Pharmaceutical (AVNC)
Avalon Pharmaceuticals (AVRX)
Biomira (BIOM)
BIOCLINICA INC (BITI)
BioProgress (BPRG)
BSD Medical (BSM)
BioSphere Medical (BSMD)
Minrad International (BUF)
Cell Genesys (CEGE)
CollaGenex Pharmaceuticals (CGPI)
Continucare (CNU)
Caraco Pharmaceutical Laboratories (CPD)
CuraGen (CRGN)
Zalicus Inc. (CRXX)
Chemgenex Pharmaceuticals (CXSP)
Cypress Bioscience (CYPB)
Labopharm (DDSS)
Dyadic International (DIL)
Digital Angel (DOC)
Datascope (DSCP)
Diversa (DVSA)
Eclipsys (ECLP)
Etrials Worldwide (ETWC)
Eurand N.V. (EURX)
Ev3 (EVVV)
PC GROUP, INC. (GAIT)
HLTH (HLTH)
Fibrocell Science, Inc. (ILE)
Lipid Sciences (LIPD)
GALECTIN THERAPEUTICS INC (PRW)
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki